Biogen Idec Excels on Tecfidera Launch
Biogen Idec Inc., of Weston, Mass., blasted consensus sales estimates for multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) out of the water, turning in $192 million in its second quarter earnings, compared to the $75 million expected by the street. The company's total revenues were $1.7 billion for the second quarter, up 21 percent over the second quarter of 2012.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter